One of the CGRP monoclonal antibody galcanezumab, has been reported effective and well-tolerated in a placebo-controlled phase III trial for preventive treatment of episodic CH and got an FDA approval in June this year. This evidence concerns the gene CALCA and cyclic hematopoiesis.